PACS Group's Co-Founder Just Completed an $8.1 Million Three-Day Campaign
PACS Group co-founder Mark Hancock completed an $8.1M three-day plan-governed campaign with a $2.51M final tranche under a March 2026 10b5-1 plan. 54.1M founder-era shares retained. Retirement context adds analytical layer.
π΄ Insider Activity Score: 94/100
Mark Hancock, co-founder and Executive Vice Chairman of PACS Group, filed a Form 4 on June 26, 2026 disclosing the terminal leg of a three-day plan-governed campaign: 61,931 common shares sold at a volume-weighted average of $40.4964 for approximately $2,508,206 β completing a 200,000-share sequence that generated approximately $8,075,786 since June 25 under a Rule 10b5-1 plan adopted on March 11, 2026. Following the complete campaign, Hancock retains 54,102,597 direct founder-era shares. The March plan ran the $8.1 million campaign. The 54.1 million retained shares are the co-founder's actual skilled nursing and post-acute care conviction. The recently announced CFO retirement adds the specific career transition context that explains the plan's timing architecture.
The March 11, 2026 Plan and the Retirement Context
The plan adoption date of March 11, 2026 β approximately three and a half months before the June 25-26 execution window β provides the temporal insulation that governs the three-day campaign. The concurrent announcement of Hancock's retirement as active CFO adds the specific personal career transition context that makes the March plan's establishment analytically coherent.
A co-founder retiring from an active executive officer role has a specific and legitimate personal financial planning rationale for establishing a systematic distribution program: the transition from active compensation-generating employment to a non-executive role reduces future income streams, creating the specific personal liquidity need that a 10b5-1 diversification plan addresses. The March plan's timing relative to the retirement announcement is the career transition context β not a directional market timing decision about PACS Group's post-acute care platform.
The 200,000-Share Three-Day Architecture
The three-day campaign discharging 200,000 aggregate shares across June 25-26 reflects a single March plan design delivering its designated multi-session output. The terminal June 26 leg of 61,931 shares β the smallest of the three sessions β is the completion tranche, clearing the residual balance of the plan's 200,000-share target after the dominant blocks executed across June 25.
The declining tranche size across the final session confirms the probe-scale-complete architecture in reverse: the dominant blocks executed in the early sessions, with the terminal leg clearing the residual balance at the available price.
The 54.1 Million Founder Share Foundation: Post-IPO Concentrated Alignment
The 54,102,597 direct founder-era shares Hancock retains β worth approximately $2.19 billion at the $40.4964 execution price β are the analytical signal that the $8.1 million campaign will entirely obscure. A co-founder retaining $2.19 billion in direct equity through a $8.1 million plan-governed retirement transition campaign has distributed less than 0.4% of the combined pre-campaign position.
The 54.1 million shares represent the foundational equity commitment of a co-founder who built PACS Group's skilled nursing and post-acute care platform from inception β a concentrated founding position whose scale makes the plan's 200,000-share output a fractional diversification event against a dominant retained foundation.
About PACS Group, Inc.
PACS Group, Inc. is a post-acute care operator providing skilled nursing and transitional care services across its multi-state facility network. Co-founder Mark Hancock is transitioning from the active CFO role to Executive Vice Chairman. Hancock retains 54,102,597 direct founder-era shares worth approximately $2.19 billion at execution prices following the completion of his March 11, 2026 Rule 10b5-1 plan's three-day $8,075,786 campaign. PACS Group trades on the NYSE under the ticker PACS.
How to Think About This
Hancock's completed three-day campaign scores 94/100 β a co-founder completing an $8.1 million plan-governed campaign concurrent with a CFO-to-Executive-Vice-Chair retirement transition, with the March adoption date providing the temporal insulation and the 54.1 million retained founder shares confirming that the post-acute care platform thesis is 99.6% intact following the plan's output.
The retirement transition explains the plan. The March adoption date governs the execution. The $2.19 billion in retained founder equity is the co-founder's actual PACS Group conviction β unchanged, undistributed, and entirely unaffected by three sessions of retirement-transition diversification.